Oligoclonal selection of nanobodies targeting vascular endothelial growth factor

References

• Ali E, Sheta M, Mohsen M. 2011. Elevated serum and tissue VEGF associated with poor outcome in breast cancer patients. Alexandria J Med. 47:217–224.
   Google Scholar
• Arezumand R, Alibakhshi A, Ranjbari J, Ramazani A, Muyldermans S. 2017. Nanobodies as novel agents for targeting angiogenesis in solid cancers. Front Immunol. 8:1746.
   PubMed Web of Science ®Google Scholar
• Bannas P, Hambach J, Koch-Nolte F. 2017. Nanobodies and nanobody-based human heavy chain antibodies as anti-tumor therapeutics. Front Immunol. 8:1603.
   PubMed Web of Science ®Google Scholar
• Beatty J, Beatty B, Vlahos W. 1987. Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Meth. 100:173–179.
   PubMed Web of Science ®Google Scholar
• Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M. 2009. Persistent elimination of ErbB-2/HER2-over-expressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis. Proc Natl Acad Sci USA. 106:3294–3299.
   PubMed Web of Science ®Google Scholar
• Biasini M, Bienert S, Waterhouse A, Arnold K, Studer G, Schmidt T, Kiefer F, Cassarino T, Bertoni M, Bordoli L, et al. 2014. SWISS-MODEL: Modelling protein tertiary and quarter-nary structure using evolutionary information. Nucleic Acids Res. 42:W252–W258.
   PubMed Web of Science ®Google Scholar
• BIOVIA. 2017. BIOVIA Discovery Studio 2017 R2: A comprehensive predictive science application for Life Sciences. San Diego (CA). Dassault SystÉmes, 2017. http://accelrys.com/products/collaborative-science/biovia-discovery-studio.
   Google Scholar
• Carter P, Lazar G. 2018. Next generation antibody drugs: Pursuit of the ‘high-hanging fruit’. Nat Rev Drug Discov. 17:197.
   PubMed Web of Science ®Google Scholar
• Ceradini D, Kulkarni A, Callaghan M, Tepper O, Bastidas N, Kleinman M, Capla J, Galiano R, Levine J, Gurtner G. 2004. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 10:858.
   PubMed Web of Science ®Google Scholar
• Chabner B, Roberts T. 2005. Chemotherapy and the war on cancer. Nat Rev Cancer. 5:65.
   PubMed Web of Science ®Google Scholar
• Cortez-Retamozo V, Backmann N, Senter P, Wernery U, De Baetselier P, Muyldermans S, Revets H. 2004. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res. 64:2853–2857.
   PubMed Web of Science ®Google Scholar
• Corti D, Kearns J. 2016. Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease. Curr Opin Immunol. 40:51–61.
   PubMed Web of Science ®Google Scholar
• de Meyer T, Muyldermans S, Depicker A. 2014. Nanobody-based products as research and diagnostic tools. Trends Biotechnol. 32:263–270.
   PubMed Web of Science ®Google Scholar
• Detalle L, van Heeke G, Allosery K, de Brabandere V, de Smedt T, de Fougerolles A. 2017. Nanobodies as inhaled biotherapeutics for lung diseases. Pharmacol Ther. 169:47–56.
   PubMed Web of Science ®Google Scholar
• Duque J, Loughlin K, Adam R, Kantoff P, Zurakowski D, Freeman M. 1999. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology. 54:523–527.
   PubMed Web of Science ®Google Scholar
• Ebrahimizadeh W, Gargari S, Javidan Z, Rajabibazl M. 2015. Production of novel VHH nanobody inhibiting angiogenesis by targeting binding site of VEGF. Appl Biochem Biotechnol. 176:1985–1995.
   PubMed Web of Science ®Google Scholar
• Ecker D, and Jones S. (Eds.) 2015. The therapeutic monoclonal antibody market. New York: Taylor & Francis.
   Google Scholar
• Ferrara N, Gerber H, LeCouter J. 2003. The biology of VEGF and its receptors. Nat Med. 9:669.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan K, Novotny W. 2005. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 333:328–335.
   PubMed Web of Science ®Google Scholar
• Flajnik M, Deschacht N, Muyldermans S. 2011. A case of convergence: Why did a simple alternative to canonical antibodies arise in sharks and camels?. PLoS Biol. 9:e1001120.
   PubMed Web of Science ®Google Scholar
• Fuh G, Wu P, Liang W, Ultsch M, Lee C, Moffat B, Wiesmann C. 2006. Structure-function studies of two synthetic anti-vascular endothelial growth factor Fab and comparison with the Avastin™ Fab. J Biol Chem. 281:6625–6631.
   PubMed Web of Science ®Google Scholar
• George M, Eccles S, Tutton M, Abulafi A, Swift R. 2000. Correlation of plasma and serum VEGF levels with platelet count in colorectal cancer: Clinical evidence of platelet scavenging? Clin Cancer Res. 6:3147–3152.
   PubMed Web of Science ®Google Scholar
• Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hammers C, Songa E, Bendahman N, Hammers R. 1993. Naturally-occurring antibodies devoid of light chains. Nature. 363:446.
   PubMed Web of Science ®Google Scholar
• Hammers C, Stanley J. 2014. Antibody phage display: Technique and applications. J Invest Dermatol. 134:1.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg R. 2011. Hallmarks of cancer: The next generation. Cell. 144:646–674.
   PubMed Web of Science ®Google Scholar
• Harmsen M, De Haard H. 2007. Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol. 77:13–22.
   PubMed Web of Science ®Google Scholar
• Hassanzadeh-Ghassabeh G, Devoogdt N, De Pauw P, Vincke C, Muyldermans S. 2013. Nanobodies and their potential applications. Nanomedicine. 8:1013–1026.
   PubMed Web of Science ®Google Scholar
• Haurum J. 2006. Recombinant polyclonal antibodies: Next generation of antibody therapeutics? Drug Discov Today. 11:655–660.
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med. 350:2335–2342.
   PubMed Web of Science ®Google Scholar
• Jamnani F, Rahbarizadeh F, Shokrgozar M, Ahmadvand D, Mahboudi F, Sharifzadeh Z. 2012. Targeting high affinity and epitope-distinct oligoclonal nanobodies to HER2 over-expressing tumor cells. Exp Cell Res. 318:1112–1124.
   PubMed Web of Science ®Google Scholar
• Jamnani F, Rahbarizadeh F, Shokrgozar M, Mahboudi F, Ahmadvand D, Sharifzadeh Z, Parhamifar L, Moghimi S. 2014. T-Cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: Towards tumor-directed oligoclonal T-cell therapy. Biochim Biophys Acta. 1840:378–386.
   PubMed Web of Science ®Google Scholar
• Kazemi-Lomedasht F, Behdani M, Bagheri K, Habibi-Anbouhi M, Abolhassani M, Arezumand R, Shahbazzadeh D, Mirzahoseini H. 2015a. Inhibition of angiogenesis in human endothelial cell using VEGF specific nanobody. Mol Immunol. 65:58–67.
   PubMed Web of Science ®Google Scholar
• Kazemi-Lomedasht F, Behdani M, Rahimpour A, Habibi-Anbouhi M, Poshang-Bagheri K, Shahbazzadeh D. 2015b. Selection and characterization of specific nanobody against human IgG. Monoclon Antib Immunodiagn Immunother. 34:201–205.
   PubMedGoogle Scholar
• Kazemi-Lomedasht F, Behdani M, Habibi-Anbouhi M, Shahbazzadeh D. 2016. Production and characterization of novel camel single domain antibody targeting mouse VEGF. Monoclon Antib Immunodiagn Immunother. 35:167–171.
   PubMedGoogle Scholar
• Kazemi-Lomedasht F, Behdani M, Bagheri K, Anbouhi M, Abolhassani M, Khanahmad H, Shahbazzadeh D, Mirzahoseini H. 2014. Expression and purification of functional human vascular endothelial growth factor-a121; The most important angiogenesis factor. Adv Pharm Bull. 4:323.
   PubMedGoogle Scholar
• Kazemi-Lomedasht F, Pooshang-Bagheri K, Habibi-Anbouhi M, Hajizadeh-Safar E, Shahbazzadeh D, Mirzahosseini H, Behdani M. 2017. In vivo immunotherapy of lung cancer using cross-species reactive vascular endothelial growth factor nanobodies. Iran J Basic Med Sci. 20:489.
   PubMed Web of Science ®Google Scholar
• Kolkman J, Law D. 2010. Nanobodies - From llamas to therapeutic proteins. Drug Discov Today Technol. 7:e139–e146.
   Google Scholar
• Könning D, Zielonka S, Grzeschik J, Empting M, Valldorf B, Krah S, Schröter C, Sellmann C, Hock B, Kolmar H, et al. 2017. Camelid and shark single domain antibodies: Structural features and therapeutic potential. Curr Opin Struct Biol. 45:10–16.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. 2015. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New Engl J Med. 373:23–34.
   PubMed Web of Science ®Google Scholar
• Laskowski R, and Swindells M., editors. 2011. LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery Roman A. Laskowski and Mark B. Swindells Journal of Chemical Information and Modeling. 2011 51 (10), 2778–2786 DOI: 10.1021/ci200227u.
   Google Scholar
• Lee C, Iorno N, Sierro F, Christ D. 2007. Selection of human antibody fragments by phage display. Nat Protocols. 2:3001.
   PubMed Web of Science ®Google Scholar
• Logtenberg T. 2007. Antibody cocktails: Next-generation biopharmaceuticals with improved potency. Trends Biotechnol. 25:390–394.
   PubMed Web of Science ®Google Scholar
• Lovell S, Davis I, Arendall W, De Bakker P, Word J, Prisant M, Richardson J, Richardson D. 2003. Structure validation by Cα geometry: ϕ, ψ and Cβ deviation. Protein Structure Function Bioinform. 50:437–450.
   PubMed Web of Science ®Google Scholar
• Muyldermans S, Baral T, Retamozzo V, De Baetselier P, De Genst E, Kinne J, Leonhardt H, Magez S, Nguyen VK, Revets H, et al. 2009. Camelid immunoglobulins and nanobody technology. Vet Immunol Immunopathol. 128:178–183.
   PubMed Web of Science ®Google Scholar
• Nikkhoi S, Rahbarizadeh F, Ahmadvand D. 2017. Oligoclonal nanobodies as an innovative targeting agent for cancer therapy: New biology and novel targeting systems. Protein Express Purific. 129:115–121.
   PubMed Web of Science ®Google Scholar
• Nikkhoi S, Rahbarizadeh F, Ahmadvand D, Moghimi S. 2018. Multivalent targeting and killing of HER2 over-expressing breast carcinoma cells with methotrexate-encapsulated tetra-specific non-overlapping variable domain heavy chain anti-HER2 antibody-PEG-liposomes: In vitro proof-of-concept. Eur J Pharm Sci.
   Web of Science ®Google Scholar
• Nowakowski A, Wang C, Powers D, Amersdorfer P, Smith T, Montgomery V, Sheridan R, Blake R, Smith L, Marks J. 2002. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci USA. 99:11346–11350.
   PubMed Web of Science ®Google Scholar
• Oliveira S, Schiffelers R, van der Veeken J, van der Meel R, Vongpromek R, en Henegouwen P, Storm G, Roovers R. 2010. Down-regulation of EGFR by a novel multivalent nanobody-liposome platform. J Controlled Release. 145:165–175.
   PubMed Web of Science ®Google Scholar
• Otrock Z, Mahfouz R, Makarem J, Shamseddine A. 2007. Understanding the biology of angiogenesis: Review of the most important molecular mechanisms. Blood Cells Mol Dis. 39:212–220.
   PubMed Web of Science ®Google Scholar
• Qi H, Lu H, Qiu H, Petrenko V, Liu A. 2012. Phagemid vectors for phage display: Properties, characteristics and construction. J Mol Biol. 417:129–143.
   PubMed Web of Science ®Google Scholar
• Ranpura V, Hapani S, Wu S. 2011. Treatment-related mortality with bevacizumab in cancer patients: A meta-analysis. JAMA. 305:487–494.
   PubMed Web of Science ®Google Scholar
• Rissiek B, Koch-Nolte F, Magnus T. 2014. Nanobodies as modulators of inflammation: Potential applications for acute brain injury. Front Cell Neurosci. 8:344.
   PubMed Web of Science ®Google Scholar
• Scott A, Wolchok J, Old L. 2012. Antibody therapy of cancer. Nat Rev Cancer. 12:278.
   PubMed Web of Science ®Google Scholar
• Sharifzadeh Z, Rahbarizadeh F, Shokrgozar M, Ahmadvand D, Mahboudi F, Jamnani F, Aghaee Bakhtiari S. 2013. Development of oligoclonal nanobodies for targeting the tumor-associated glycoprotein 72 antigen. Mol Biotechnol. 54:590–601.
   PubMed Web of Science ®Google Scholar
• Shibuya M. 2001. Structure and function of VEGF/VEGF-receptor system involved in angio-genesis. Cell Structure Funct. 26:25–35.
   PubMed Web of Science ®Google Scholar
• Spadiut O, Capone S, Krainer F, Glieder A, Herwig C. 2014. Microbials for the production of monoclonal antibodies and antibody fragments. Trends Biotechnol. 32:54–60.
   PubMed Web of Science ®Google Scholar
• Spangler J, Neil J, Abramovitch S, Yarden Y, White F, Lauffenburger D, Wittrup K. 2010. Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci USA. 107:13252–13257.
   PubMed Web of Science ®Google Scholar
• Swain S, Baselga J, Kim S, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero J, Schneeweiss A, Heeson S, et al. 2015. Pertuzumab, trastuzumab, and docetaxel in HER2+ metastatic breast cancer. New Engl J Med. 372:724–734.
   PubMed Web of Science ®Google Scholar
• Trapani J, Darcy P. 2017. Immunotherapy of cancer. Austral Family Physician. 46:194.
   PubMed Web of Science ®Google Scholar
• Walker A, Chung C, Neu M, Burman M, Batuwangala T, Jones G, Tang CM, Steward M, Mullin M, Tournier N, et al. 2016. Novel interaction mechanism of a domain antibody based inhibitor of human vascular endothelial growth factor with greater potency than ranibizumab and bevacizumab and improved capacity over aflibercept. J Biol Chem. 291:5500–5511.
   PubMed Web of Science ®Google Scholar